SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study
Mangia, A.; Cenderello, G.; Copetti, M.; Verucchi, G.; Piazzolla, V.; Lorusso, C.; Santoro, R.; Squillante, M.M.; Orlandini, A.; Minisini, R.; Ciancio, A. SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study. Cells 2019, 8, 313. https://doi.org/10.3390/cells8040313
Mangia A, Cenderello G, Copetti M, Verucchi G, Piazzolla V, Lorusso C, Santoro R, Squillante MM, Orlandini A, Minisini R, Ciancio A. SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study. Cells. 2019; 8(4):313. https://doi.org/10.3390/cells8040313
Chicago/Turabian StyleMangia, Alessandra, Giovanni Cenderello, Massimiliano Copetti, Gabriella Verucchi, Valeria Piazzolla, Celeste Lorusso, Rosanna Santoro, Maria M. Squillante, Alessandra Orlandini, Rosalba Minisini, and Alessia Ciancio. 2019. "SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study" Cells 8, no. 4: 313. https://doi.org/10.3390/cells8040313


